Navigation Links
Financing of biotech companies so far in 2005: A Midwest odyssey

For a biotech company, raising money is a saga that never ends.

Just as you complete a round, you have to do two things: execute on the timely achievement of key milestones you identified for your new investors and look at the structuring of your next financing and where and who the money will come from. Most angel investors aren't repeti......

Full article >>> bove, only two of the companies had a share price above $10 per share, which is one indicator of IPO strength. Aspreva Pharmaceuticals was the only company to have a significant amount of money raised (i.e. above $75 million). So what makes for a successful IPO? It is a combination of factors including:

Market timing
Company credentials
Management team and track record
Pri......

Full article >>> s from a VC panel at the InvestMidwest conference, which was held recently in Kansas City. His remarks were in response to another west coast VC's comment that most biotech companies on the west coast are in a unique situation in that they are getting multiple term sheets for the funding of their deals. This is allowing them to pick the best deal.

Churchwell commented that the situation i......

Full article >>> illion last year (or a decline of 19 percent).

A key indicator for the Midwest biotech sector was VC activity in biotech. The first quarter showed a total of $781 million versus almost $1.4 billion last year (or a decline of 43 percent). Ouch!



Though we don't yet have data to show how the Midwest fared in this area, I'm willing to bet that it ......

Full article >>> lines.

The ramifications of the Bone Care deal are both good and bad for the Midwest. On the downside, there are only 25 publicly traded biotech companies in the Midwest. Two have been picked off this year: Orphan Medical (by Jazz Pharmaceuticals) and now Bone Care (also don't forget Esperion and Cima Labs in 2003).

On the positive side, there are some new multi-millionaire inves......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 05/11/05


Related biology technology :

1. Financing life science: The ongoing saga
2. Seed-Stage Venture Financing
3. Quintessence Secures Financing
4. The state of global biotech: An Ernst & Young perspective
5. Olympics of biotechnology has international flavor
6. Getting noticed in Genetown: Wisconsin biotech on display
7. Madison biotech NimbleGen files for IPO; one of states best-funded firms
8. Wisconsin biotech firm receives $107K NIH grant
9. Manufacturing partnership will move into biotech and biomedical spaces
10. Wisconsin wont get Georgia biotech without a fight
11. The 10 biggest events shaping biotech in 2006
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):